Gland Pharma Limited (BOM:543245)
India
· Delayed Price · Currency is INR | Market Cap | 290.10B |
| Revenue (ttm) | 61.13B |
| Net Income (ttm) | 8.47B |
| Shares Out | n/a |
| EPS (ttm) | 51.42 |
| PE Ratio | 34.24 |
| Forward PE | 25.48 |
| Dividend | 18.00 (1.01%) |
| Ex-Dividend Date | Aug 14, 2025 |
| Volume | 1,983 |
| Average Volume | 15,736 |
| Open | 1,775.00 |
| Previous Close | 1,773.30 |
| Day's Range | 1,745.90 - 1,775.00 |
| 52-Week Range | 1,382.10 - 2,130.00 |
| Beta | n/a |
| RSI | 54.55 |
| Earnings Date | May 15, 2026 |
About Gland Pharma
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neopla... [Read more]
Financial Performance
In fiscal year 2025, Gland Pharma's revenue was 56.17 billion, a decrease of -0.85% compared to the previous year's 56.65 billion. Earnings were 6.99 billion, a decrease of -9.57%.
Financial StatementsNews
Gland Pharma reappoints Naina Lal Kidwai as independent director with special remuneration terms
Gland Pharma has announced the reappointment of Ms. Naina Lal Kidwai as an Independent Director. The decision, which was initially proposed in a postal ballot notice dated April 9, 2026,…
Pharma sector stocks today, April 7: Shukra Pharma up 5%, Max Healthcare falls 2.44%, Gland Pharma down 1.68%
Pharmaceutical sector stocks traded mostly lower in early deals on April 7, 2026. The S&P BSE Healthcare Index stood at 41,286.7, down 0.6%. The index has declined 5.6% over the…
Pharma sector stocks today, March 30: Suven Life surge 7.88%, Wockhardt up 3.27%, Gland Pharma falls 2.36%
As of approximately 9:33 AM IST on March 30, 2026 (BSE prices) and 9:34 AM IST (NSE prices), most pharma sector stocks on the BSE and NSE were trading in…
Pharma sector stocks surge today, March 18: Alembic jumps 2.87%, Panacea Biotec up 2.84%, Gland Pharma rises 2.69%
The pharmaceutical sector stocks in India showed positive movement on March 18, 2026, during early trading hours, with many scrips recording gains on both BSE and NSE. The S&P BSE…
Gland Pharma gets USFDA tentative approval for Brimonidine Tartrate Ophthalmic Solution
Gland Pharma Limited has received tentative approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Brimonidine Tartrate Ophthalmic Solution, 0.025% (OT...
Pharma sector stocks down today, Feb 24: AstraZeneca Pharma falls 1.72%, Alembic Pharma down 1.38%, Gland Pharma drops 1.24%
The Indian pharmaceutical sector experienced a modest decline on February 24, 2026, amid broader market weakness. The S&P BSE HEALTHCARE...
Gland Pharma gets USFDA nod for Zoledronic Acid Injection for US market
Gland Pharma Limited has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug...
Gland Pharma shares rally sharply over 8% as Q3 revenue rises 22.5% YoY to Rs Rs 1,695 crore, net profit up 27.7%
Gland Pharma shares surged over 8% in early morning trade after the company reported a strong set of consolidated results...
Top stocks for trade today, Jan 29: Wipro, Mahindra, Garden Reach, Gland Pharma, Larsen & Toubro and more
Indian equities are likely to see stock-specific action today, January 29, as several companies announced quarterly results, partnerships, and order...
Gland Pharma Ltd (NSE:GLAND) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and ...
Gland Pharma Ltd (NSE:GLAND) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansions
Q3 2026 Gland Pharma Ltd Earnings Call Transcript
Q3 2026 Gland Pharma Ltd Earnings Call Transcript
Gland Pharma Transcript: Q3 25/26
Q3 FY 2026 delivered 22% revenue growth and 25% higher adjusted EBITDA, driven by strong U.S. and European performance, Cenexi turnaround, and new product launches. Five-year CapEx of INR 2,000 crore targets capacity expansion, with 12%-13% growth expected for FY 2027 and a 15% five-year CAGR.
Gland Pharma Q3 Results: Revenue jumps 22.5% YoY to Rs 1,695 crore, net profit up 27.5% YoY
Gland Pharma has announced its Q3 financial results, reporting strong year-on-year growth across key operational and profitability metrics, supported by...
Gland Pharma Ltd (NSE:GLAND) Q3 2026 Earnings Report Preview: What To Expect
Gland Pharma Ltd (NSE:GLAND) Q3 2026 Earnings Report Preview: What To Expect
Pharma sector stocks today, Jan 23: Dr. Reddy’s Lab jumps 2.14%, Gland Pharma falls 1.71%, Torrent Pharma down 0.80%
The Indian pharma sector stocks showed mixed performance as of 10:20 AM IST on January 23, 2026. The broader market...
Gland Pharma shares surge nearly 4% after getting USFDA approval for Olopatadine Hydrochloride Ophthalmic Solution 0.7% (OTC)
Gland Pharma shares climbed nearly 4% after the company announced that it has received approval from the United States Food...
Top stocks to watch today, January 8: Infosys, Tata Steel, HUDCO, Gland Pharma, Angel One, Cipla and more
Indian equity markets are likely to begin Thursday’s session on a cautious note. Trends from global indices and GIFT Nifty...
Gland Pharma receives USFDA approval for Olopatadine Hydrochloride Ophthalmic Solution 0.7% (OTC)
Gland Pharma Limited, a leading injectable and ophthalmic-focused pharmaceutical company, has received approval from the United States Food and Drug...
Nomura cautious on Gland Pharma, trims estimates post Q2 miss but sees long-term visibility
Nomura has maintained its neutral rating on Gland Pharma with a target price of ₹2,000 per share after the company...
Gland Pharma Ltd (NSE:GLAND) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and ...
Gland Pharma Ltd (NSE:GLAND) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion
Q2 2026 Gland Pharma Ltd Earnings Call Transcript
Q2 2026 Gland Pharma Ltd Earnings Call Transcript
Gland Pharma Transcript: Q2 25/26
Q2 FY2026 saw 6% revenue growth and margin expansion, with strong U.S. and Cenexi performance. Management maintains mid-teens growth guidance for FY2026, expecting a stronger H2 driven by major launches and operational improvements at Cenexi.
Gland Pharma Q2 Results: Revenue jumps 5.8% YoY to Rs 1,487 crore, net profit up 12.2%
Gland Pharma reported a steady performance in the September quarter (Q2 FY26), with moderate year-on-year growth across key financial metrics....
Gland Pharma Ltd (NSE:GLAND) Q2 2026 Earnings Report Preview: What To Expect
Gland Pharma Ltd (NSE:GLAND) Q2 2026 Earnings Report Preview: What To Expect
These Indian pharma stocks tumble as Trump announces 100% tariff on branded drugs
Indian pharmaceutical shares came under heavy selling pressure on Friday, September 26, after U.S. President Donald Trump announced a 100% tariff on branded and patented pharmaceutical drugs starting ...